![Joseph Lobacki](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph Lobacki
Director/Board Member at SUTRO BIOPHARMA, INC.
Net worth: - $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Daniel Calkins | M | 37 | 6 years | |
David J. Scott | M | 71 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 years |
Jane Chung | F | 53 | 3 years | |
Sean E. Harper | M | 61 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 years |
William Newell | M | 66 | 15 years | |
Christian Lange | M | 44 | 7 years | |
Nicki Vasquez | M | 61 | 9 years | |
Jon Wigginton | M | 62 | 4 years | |
Heidi Hunter | F | 65 | 3 years | |
Andre Hoekema | M | 67 |
Artax Biopharma, Inc.
![]() Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | 1 years |
Michael Dybbs | M | 49 | 6 years | |
Henry Heinsohn | M | - | - | |
Linda Fitzpatrick | F | 67 | 16 years | |
Connie Matsui | F | 70 | 5 years | |
Edward Albini | M | 66 | 11 years | |
Jeffery Smisek | M | 69 | 7 years | |
John Freund | M | 70 | 10 years | |
Daniel Petree | M | 68 | - | |
James Panek | M | 71 | 4 years | |
Anne Borgman | M | 56 | 1 years | |
Carlos Lugo | M | - | - | |
Werner Rubas | M | - | 3 years | |
David Pauling | M | - | - | |
Hans-Peter Gerber | M | 61 | 1 years | |
Diana Landa | F | - | 4 years | |
Regina Cheng | F | - | 4 years | |
Craig Berman | M | - | 4 years | |
Robert Bradway | M | 61 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 years |
Kevin Sharer | M | 76 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 years |
Brian M. McNamee | M | 67 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 years |
Steve Michel | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Clarence Machado | M | 60 | 21 years | |
James B. Wyngaarden | M | 99 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 23 years |
Vin Milano Milano | M | 60 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | - |
James Geraghty | M | 69 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 19 years |
Joseph Chiapponi | M | 55 | 6 years | |
David Hung | M | 67 | 21 years | |
Henri A. Termeer | M | 78 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 28 years |
Lawrence David Mayer | M | 68 | 17 years | |
Christian Itin | M | 59 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 6 years |
Michael Dougherty | M | 66 | 3 years | |
Dawn Svoronos | F | 70 | 3 years | |
Christopher Viehbacher | M | 64 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Mark Goldberg | M | 69 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 24 years |
Julie Feder | F | 54 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 1 years |
Mark Smith | M | 37 | 6 years | |
Andrew Noh | M | - | 4 years | |
Joseph A. Mollica | M | 83 | 9 years | |
Scott Jackson | M | 59 | 9 years | |
Matthias Alder | M | 59 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 6 years |
Jennifer J. Rhodes | F | 53 | 3 years | |
Daniel Janney | M | 58 | - | |
Douglas Giordano | M | 61 | - | |
Bruce Cozadd | M | 60 | - | |
Abdul-Wahab Umari | M | - |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 2 years |
Scott Morenstein | M | 48 | 3 years | |
Jonathan Peacock | M | 66 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Jean Bizzari | M | 69 | 1 years | |
Mark A. Nowak | M | - |
Boston College
| 7 years |
Robert S. Farrington | M | - |
Boston College
| 7 years |
Linda Bain | F | 53 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 3 years |
Steven J. Burakoff | M | 81 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
Karen Smith | M | 56 | - | |
Matthew Young | M | 54 | - | |
Kapil Dhingra | M | 64 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 3 years |
Gloria Matthews | M | - |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 6 years |
Andrew Powell | M | 66 | 1 years | |
Julian Baker | M | 57 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 4 years |
Sean Flynn | M | 50 | 1 years | |
Brian Schiller | M | - |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 10 years |
Ralph Victor Whitworth | M | 68 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
John Doyle | M | 46 | 2 years | |
Zain Kassam | M | 42 | 4 years | |
Peter A. Pellegrino | M | 49 | 1 years | |
Maureen Bennett | F | - |
Boston College
| 7 years |
Conrad J. Bletzer | M | - |
Boston College
| 7 years |
V. Lawlis | M | 72 | 16 years | |
Richard Kollender | M | 54 | 4 years | |
Nicole Vitullo | F | 66 | 11 years | |
Gina Consylman | F | 52 | 3 years | |
Kathryn Falberg | F | 63 | 3 years | |
Joseph Slattery | M | 59 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 5 years |
Wendy Yarno | F | 68 | 3 years | |
Richard F. Syron | M | 80 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | - |
S. Phanstiel | F | 65 | 6 years | |
Richard A. Bierly | M | 68 | 2 years | |
Peter Wirth | M | 73 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 15 years |
Alan Smith | M | 78 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 22 years |
Louis Brenner | M | 54 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 6 years |
Peter W. Letendre | M | 66 |
Massachusetts College of Pharmacy & Health Science
| 6 years |
C. Hartley | M | 81 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 17 years |
Shalini Sharp | F | 49 | 5 years | |
Kelvin Neu | M | 50 |
Idera Pharmaceuticals, Inc.
![]() Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | 5 years |
Norman A. Abood | M | - |
Massachusetts College of Pharmacy & Health Science
| 6 years |
Henry E. Blair | M | 80 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 26 years |
Bryan T. Rich | M | 67 |
Boston College
| 4 years |
Christine M. Granfield | F | 56 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 13 years |
Paula Ragan | M | 54 |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 5 years |
John K. Mara | M | 69 |
Boston College
| 4 years |
Shawna Ferguson | F | - |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | 12 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joseph Lobacki
- Personal Network